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Introduction: Epidermal growth factor receptor (EGFR) mutations
are more common in lung adenocarcinoma and in female patients of
East-Asian origin. We aimed to assess the expression of female
hormone receptors in East-Asian lung adenocarcinomas, their cor-
relation with EGFR mutations, and prognostic significance.
Methods: Estrogen receptor (ER), ER, progesterone receptor
(PR), and Her-2 expression were examined using immunohisto-
chemical methods on 109 lung adenocarcinoma cases. EGFR mu-
tations were analyzed by partially denaturing high performance
liquid chromatography. Association of hormone receptor with
clinical factors was assessed using the Fisher’s exact test. Asso-
ciations with survival were assessed using the Cox proportional
hazard model.
Results: Using scoring criteria routinely used for breast cancer,
there were four (4%) ER, one (1%) ER, six (6%) PR, and one
(1%) Her-2 positive cases. Considering any staining as positive, 14
(14%) ER, 10 (9%) ER, 12 (12%) PR, and 26 (24%) Her-2 cases
were positive. Thirty-nine patients (39%) had EGFR mutations.
ER positivity was significantly associated with ER and PR
positivity. There were more EGFR mutations seen in tumors with
ERß positivity (60%) compared with those with negative expression
(37.9%), and there was a trend toward a poorer outcome for patients
with tumor that were positive for ERß and Her-2.
Conclusions: We found that ER, ER, PR, and Her-2 expression
in lung adenocarcinoma are present but limited. This suggests that
hormonal influence may not be an important factor to account for the
high prevalence of lung cancer among the East-Asian women.
Key Words: Hormone receptors, EGFR mutations, Prognosis, Ad-
enocarcinoma, Females.
(J Thorac Oncol. 2010;5: 17–22)
Differences in epidemiological characteristics betweenmen and women with non-small cell lung cancer
(NSCLC), the putative increased susceptibility of women to
lung cancer, and the possible role of hormonal factors among
women has prompted many molecular studies to identify the
biologic basis for the differences between the sexes.1 In-
cluded among these studies are the assessments of hormonal
receptors (HR) in NSCLC.
Estrogen receptors (ER) and progesterone receptors
(PR) have been shown to be expressed in lung carcinoma,
especially adenocarcinoma.2–8 The frequency of expression
of ER varies between 0% and 96.8%, whereas that for PR
expression varies between 21.8% and 34.7%. Several of the
earlier studies, including a large study of 248 patients,2 did
not find significant expression of ER or PR in NSCLC tissues.
A limitation of these earlier studies was the usage of anti-
bodies that did not distinguish ER or ER, which could
have contributed to variable results. Recently, several groups
reported that both ER and ER are expressed in
NSCLC.9–13 It is believed that ER protein present in the
lungs are mainly splice variants that may or may not be
functional, and ER may be a more important receptor in
lung cancer.
Her-2/neu is a member of the erbB family of receptors
that play a role in the development of many solid tumors.14
Several studies have evaluated Her-2/neu expression in lung
cancers and report varies from 16 to 57% of patients with
NSCLC, with adenocarcinoma showing the highest rates of
overexpression.15–18 Most of the studies have included a
heterogenous group of NSCLC, and none of them have
looked at the expression of ER/ER/PR/Her-2 on the same
tumor samples.
Since the finding of somatic epidermal growth factor
receptor (EGFR) mutations in NSCLC, many studies have
found higher frequency in tumors from East-Asians, women,
never smokers, and adenocarcinomas.19–20 With the coinci-
dent sex bias in the prevalence of EGFR mutations in
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NSCLC, it is plausible that there may be interactions between
HRs and EGFR mutations. With a high proportion of women
and never smokers in our East-Asian NSCLC population,21
we aimed to study the expression and prognostic significance
of HRs in a homogenous population of lung adenocarcinoma
and to test for correlations between HRs and the presence of
EGFR mutations.
PATIENTS AND METHODS
Patients
Patients involved in this study were selected from a
database of patients with NSCLC diagnosed during the period
1999–2002 at our institution. The characteristics of these
patients were reported previously.21 This study was approved
by our institutional review board. The main selection crite-
rion in this study was a diagnosis of adenocarcinoma based
on the pathology reports. Although there was no formal
pathology review by a single pathologist to confirm adeno-
carcinoma, most of the tumor samples were read by our
pathologist (K.L.C.). Four hundred ninety-seven patients with
adenocarcinoma were identified, and among them, 109 pa-
tients had sufficient tissue blocks available for analysis of
ER/ER/PR/Her-2 expression and EGFR mutations.
Immunohistochemistry
Five micrometer sections were dewaxed and underwent
antigen retrieval by boiling in 1 Antigen Retrieval Solution
(DAKO, Oslo, Norway) for 5 minutes at 120°C (20–25 p.s.i.)
in a T/T Mega Microwave Oven (Milestone, Sorsolie, Italy).
The slides were then cooled in the buffer for 10 to 20 minutes
and rinsed in three changes of deionized water. Slides were
then processed in the Cytomation autostainer (Dako) accord-
ing to the following program: hydrogen peroxide for 5 min-
utes; phosphate-buffered saline (PBS) rinse; protein block for
30 minutes; PBS buffer rinse; primary antibody in antibody
diluent for 60 minutes; PBS buffer rinse; secondary antibody
Link  horseradish peroxidase for 15 minutes; 2 buffer
rinse; 3,3-diaminobenzidine for 5 minutes; and 2 water
rinse. Slides were then counterstained with hematoxylin for 1
minute, rinsed in deionized water, dehydrated, and cover-
slipped. Antibodies used were monoclonal mouse antihuman
ER (1D5; 1:500 dilution), monoclonal mouse antihuman
ER (PPG5/10; 1:100), monoclonal mouse antihuman PR
(PgR 636; 1:50), and rabbit antihuman C-erbB-2 (A0485;
1:250). All reagents were from Dako.
Immunohistochemical staining was assessed for the
extent of positivity (determined by the percentage of positive
tumor cells) and their staining intensity (1, weak; 2,
moderate, and 3, strong). The cases were scored in two
ways. In the first method based on routine scoring used in
breast cancer, positive results included samples with at least
one  staining in 10% of tumor cells. The second method
considered any level of staining as positive.
EGFR Mutational Analysis
EGFR mutations were detected and sequenced using a
partially denaturing high performance liquid chromatogra-
phy-based protocol described previously.22 Aberrantly mi-
grating peaks in partially denaturing high performance liquid
chromatography analysis were considered to indicate a mu-
tation. These mutations were not sequenced due to low
sample availability.
Statistical Analysis
Comparison of the median age between expression
status of HRs was done using the Mann-Whitney U test.
Association of HR expression with each other and with
clinical factors such as sex, race, smoking status, stage, or
presence of EGFR mutations was assessed using the Fisher’s
exact test. Overall survival for each patient was measured
from the date of diagnosis to the date of death or the date
patient was last known to be alive for censored observation.
Kaplan-Meier method was used to estimate the overall sur-
vival function and median overall survival time. Cox propor-
tional hazard model was used to estimate the crude and
adjusted hazard ratio. p values of less than 0.05 were consid-
ered as being statistically significant. The software used for
the analyses was STATA version 9.1 (College Station, TX).
RESULTS
Patient Characteristics
Overall patients’ characteristics are summarized in Ta-
ble 1. The median age at diagnosis was 62 years. Sixty
percent of patients were men, and majority (91%) was Chi-
nese. Forty-seven were never smokers (46%), 14 were former
smokers (14%), and 41 were current smokers (40%). Forty-
nine patients (45%) had stage I/II disease for which surgical
resection was performed with curative intent, and among
them, only one patient received postoperative adjuvant
radiotherapy and none received adjuvant chemotherapy.
Thirty-seven patients (34%) had stage IIIA/IIIB disease, of
which 15 underwent surgical resection as part of the
multimodality treatment with combination of chemother-
apy with/without radiation therapy. Twenty-three patients
(21%) had stage IV disease.
Expression of ER/ER/PR/Her-2 and EGFR
Mutational Status
Of the 109 patient samples, 102 patients (94%) had
conclusive results for ER and PR, 106 (97%) for ER, 107
(98%) for Her-2, and 100 (92%) for EGFR mutations (Table 1).
Using the criteria used routinely in breast cancer analysis, four
patients (4%) were ER positive, one (1%) ER, six (6%) PR, and
one (1%) Her-2 positive. Considering less conservative criteria of
any staining as positive, 14 (14%) were ER positive, 10 (9%)
ER, 12 (12%) PR, and 26 (24%) Her-2 positive. Subse-
quent analyses are based on expression determined accord-
ing to the less conservative criteria.
Thirty-nine patients (39.0%) had EGFR mutations.
Twenty-one patients (53.8%) had mutations at exon 19, seven
(17.9%) at exon 20, seven (17.9%) at exon 18, and four
(10.3%) at exon 21. Table 1 summarizes the correlations
between the HRs, clinical factors, and EGFR mutation status.
There was no significant association between the HRs and
clinical factors such as sex, race, smoking status, stage, or
presence of EGFR mutation. Table 2 summarizes the associ-
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ations of the expression of the HRs with each other. ER
positivity was significantly associated with ER and PR
positivity.
Survival Analysis
Table 3 summarizes the hazard ratios and significance
of the HRs and clinical factors. Advanced stage and signifi-
cant weight loss were variables of poor prognosis. There was
no statistically significant difference in overall survival be-
tween patients according to any of the HRs.
DISCUSSION
We found that only a small percentage of our patients
with lung adenocarcinoma express ER and ER. Using the
criteria used routinely in the assessment of breast cancers,
only 4% of tumors are ER positive, and 1% were ER
positive. Even with the less conservative criteria, 14% were
positive for ER and 9% for ER. This frequency is much
lower than the other studies on ER/ER expression in
NSCLC.10,13 The antibodies that we use are routinely used in
TABLE 1. Frequency of Expression of the Hormonal Receptors According to Clinical Factors and EGFR Mutation Status
Variable All
ER ER PR Her2
Negative Positive Negative Positive Negative Positive Negative Positive
Age (yr)
Median 62 62 63 65 58.5 62.5 69.5 65 63
Interquartile range 54–69 54.5–71 56–71 56–71 52–70 56–71 59.5–72.5 56–71 56–71
Sex (%)
Male 65 (59.6) 52 (59.1) 9 (64.3) 56 (58.3) 7 (70.0) 53 (58.9) 8 (66.7) 49 (60.5) 16 (61.5)
Female 44 (40.4) 36 (40.9) 5 (35.7) 40 (41.7) 3 (30.0) 37 (41.1) 4 (33.3) 32 (39.5) 10 (38.5)
Race (%)
Chinese 99 (90.8) 79 (89.8) 14 (100.0) 86 (89.6) 10 (100.0) 80 (88.9) 12 (100.0) 71 (87.7) 26 (100.0)
Malay 8 (7.4) 7 (8.0) 0 (0) 8 (8.3) 0 (0) 8 (8.9) 0 (0) 8 (9.9) 0 (0)
Indian 1 (0.9) 1 (1.1) 0 (0) 1 (1.0) 0 (0) 1 (1.1) 0 (0) 1 (1.2) 0 (0)
Others 1 (0.9) 1 (1.1) 0 (0) 1 (1.0) 0 (0) 1 (1.1) 0 (0) 1 (1.2) 0 (0)
Smoking status (%)
Smoker 47 (46.1) 31 (37.3) 6 (50.0) 33 (36.7) 6 (66.7) 31 (36.9) 6 (54.5) 32 (42.1) 9 (37.5)
Former smoker 14 (13.7) 12 (14.5) 2 (16.7) 13 (14.4) 1 (11.1) 13 (15.5) 1 (9.1) 13 (17.1) 1 (4.2)
Never smoker 41 (40.2) 40 (48.2) 4 (33.3) 44 (48.9) 2 (22.2) 40 (47.6) 4 (36.4) 31 (40.8) 14 (58.3)
AJCC stage (%)
I–IIIA 78 (71.6) 66 (75.0) 9 (64.3) 68 (70.8) 8 (80.0) 65 (72.2) 11 (91.7) 59 (72.8) 18 (69.2)
IIIB–IV 31 (28.4) 22 (25.0) 5 (35.7) 28 (29.2) 2 (20.0) 25 (27.8) 1 (8.3) 22 (27.2) 8 (30.8)
EGFR mutation (%)
Wild type 61 (61.0) 48 (59.3) 8 (66.7) 54 (62.1) 4 (40.0) 50 (61.7) 6 (50.0) 45 (60.8) 15 (62.5)
Mutant 39 (39.0) 33 (40.7) 4 (33.3) 33 (37.9) 6 (60.0) 31 (38.3) 6 (50.0) 29 (39.2) 9 (37.5)
AJCC, American Joint Committee on Cancer; EGFR, Epidermal Growth Factor Receptor; ER, estrogen receptor; PR, progesterone receptor.
TABLE 2. Association of the Expression of Hormonal Receptors with Each Other
Variable All
ER ER PR Her2
Negative Positive Negative Positive Negative Positive Negative Positive
ER (%)
Negative 88 (86.3) — — 82 (90.1) 5 (50.0) 79 (92.9) 8 (57.1) 66 (76.7) 9 (64.3)
Positive 14 (13.7) — — 9 (9.9) 5 (50.0) 6 (7.1) 6 (42.9) 20 (23.3) 5 (35.7)
ER (%)
Negative 96 (90.6) 82 (90.1) 5 (50.0) — — 86 (93.5) 4 (40.0) 71 (74.7) 8 (80.0)
Positive 10 (9.4) 9 (9.9) 5 (50.0) — — 6 (6.5) 6 (60.0) 24 (25.3) 2 (20.0)
PR (%)
Negative 90 (88.2) 79 (92.9) 8 (57.1) 86 (93.5) 4 (40.0) — — 68 (88.3) 22 (88.0)
Positive 12 (11.8) 6 (7.1) 6 (42.9) 6 (6.5) 6 (60.0) — — 9 (11.7) 3 (12.0)
Her2 (%)
Negative 81 (75.7) 66 (76.7) 9 (64.3) 71 (74.7) 8 (80.0) 68 (88.3) 22 (88.0) — —
Positive 26 (24.3) 20 (23.3) 5 (35.7) 24 (25.3) 2 (20.0) 9 (11.7) 3 (12.0) — —
Underlined frequencies indicate associations with p  0.05.
ER, estrogen receptor; PR, progesterone receptor.
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immunohistochemical staining of ER/PR/Her-2 in the clinical
setting. The antibody for ER that we used identifies the NH2
domain of ER, and previous studies using this antibody
have also reported low expression frequencies with this
antibody.2 Kawai et al.10 found no positive staining when
they used a monoclonal antibody against the N-terminus of
ER, whereas positive staining was observed with antibodies
against the C-terminus of ER. The significance of the ER
variant that lacks the N-terminus is unknown at the present
moment. ER has two transcriptional activation domains, the
N-terminal activation domain AF-1 and the C-terminal do-
main AF-2, and most of the coactivators interact with the
AF-2 domain. Thus, the N-terminus may have redundant
function in lung cancer cells, whereas the C-terminus is
required for association with coactivators such as the mixed
lineage leukemia 2 complex. The mixed lineage leukemia 2
complex has been shown to bind to ER near the C-terminus
and may play a central role in the growth of ER-positive
cancer cells.23
The expression of ERß in our study is much lower than
that of Skov et al.13 who reported an expression of 69%. Skov
et al. performed IHC on 104 patients with NSCLC diagnosed
during the period of 1989–1992. Majority (97%) of their
patients were stages I to IIIA, with 68% men, 38% adeno-
carcinoma, and 54% squamous cell carcinoma. This is in
contrast to our study population where 71.6% were stages I to
IIIA, 40.4% men, and 100% adenocarcinoma. They used the
same clone of antihuman ER (PPG5/10) but used it at a
higher concentration of 1:10, when compared with 1:100 in
our study. They found 84% of tumors were positive for ERß,
with 77% of them being of weak or very weak intensity. The
most likely reason for the discrepancies between the study by
Skov et al. and ours is the technique used, including the
different concentrations of antibody, although differences in
the study population may have some contributions.
PR was expressed in 12% of cases in our study. PR
gene is a downstream target of ER24 activation and can be
considered a surrogate marker for ER expression although ER
and PR expression can be discordant within the same tumor.
In a previous study by Cagle et al.,3 the authors found six of
19 resected NSCLC specimens were positive for PR expres-
sion using an old technique of prelabeled sucrose gradient
method. In a later study by Nunno et al.,2 they found no PR
expression in 248 patients with NSCLC using PR monoclonal
antibodies. Differences in techniques used is the main reason
for the differences in the studies but most studies found
relatively low percentage of expression of PR in lung cancer.
Although the expression frequency of Her-2 is 24%, this is
based on the less conservative criteria and from the clinical
experience in breast cancer. Her-2 is important only if ex-
pressed at least three , and based on that, only one patient
was Her-2 positive. In our patients with NSCLC, we noted
that a small subgroup have positive expression for all three
receptors, see Table 2. The implication of this is that the
presence of HRs staining does not exclude the diagnosis of
NSCLC.
Other studies found differential expression of ER/
ERß by sex. Schwartz et al.25 found that ER-ß positivity was
present in 61% of tumor tissue samples, with 70.3% in men
and 58.3% in women. Interestingly, we did notice a trend
toward a higher percentage of men having positive ER/
ERß/PR expression, when compared with women: nine of 52
(17%) men versus six of 36 (13.9%) women for ER, seven
of 56 (12.5%) men versus three of 40 women (7.5%) for ERß
and eight of 53 (15.1%) men versus four of 37 (10.8%)
women for PR. However, the numbers are too small to make
any definitive conclusion. One of the major reasons for
differences in ER/PR/Her-2 expressions is the techniques
used as studies have used different concentrations and clones
of antibodies with varying incubation times. In addition,
archival tissues were used for many of these studies and the
varying age of the tissues and the different storage conditions
could have contributed to the variable results seen. We used
tumor samples from the period of 1999 to 2002, whereas the
study by Nose et al.,26 which will be mentioned later, used
more recent tumor tissues. The efficacy of IHC can diminish
over time if the storage conditions are not optimal and the use
of older tissues in our study could have contributed to the low
expression in our study. However, in the earlier mentioned
study by Skov et al.,13 the tumor samples used were almost 10
years older than the tissues used in our study and the authors
TABLE 3. Univariate Analysis of Clinical Characteristics and
Overall Survival
Variable
Categories/
Units N HR
95% Confidence
Interval p
Age Yr 109 1.003 0.980–1.028 0.8
Estrogen
receptor 
Negative 102 1
Positive 1.64 0.871–3.080 0.1
Estrogen
receptor 
Negative 106 1
Positive 1.42 0.703–2.874 0.3
Her2 Negative 107 1
Positive 1.47 0.871–2.496 0.1
Progesterone
receptor
Negative 102 1
Positive 1.18 0.597–2.325 0.6
AJCC stage IA/IB/IIA 109 1
IIB/IIIA
IIIB/IV 5.10 3.056–8.495 0.001
EGFR Wild type 100 1
Mutant 0.65 0.387–1.080 0.1
Sex Female 109 1
Male 1.45 0.888–2.351 0.1
Smoking status Nonsmoker 102 1
Former smoker 0.84 0.381–1.839 0.7
Smoker 1.54 0.929–2.540 0.1
Comorbidities No 108 1
Yes 1.35 0.848–2.158 0.2
Significant loss
of weight
No 99 1
Yes 5.67 2.285–14.067 0.001
ECOG 0 104 1
1 2.25 0.551–9.228 0.3
2 3.74 0.623–22.512 0.1
3 1.93 0.174–21.468 0.6
AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncol-
ogy Group; EGFR, Epidermal Growth Factor Receptor; HR, hazard ratio.
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managed to find a high percentage of ERß expression. Be-
cause of the requirement of sufficient tissues for immunohis-
tochemistry (IHC), it was not possible to accrue consecutive
patients who presented at our center with a selection bias
toward surgically resected patients.
We also looked at the possibility that the HR status of
the tumor could correlate with the presence of EGFR muta-
tions. A small study by Willmore-Payne et al.27 previously
found that ER/PR staining did not correlate with EGFR
mutations, but their number of cases with EGFR mutation
(n  6) was small. However, a recent Japanese study on
surgically resected adenocarcinoma reported a high expres-
sion of ER (49.4%) and ER (48.5%) among 447 patients,
and the authors also found that strong nuclear expression of
ER was independently associated with the EGFR muta-
tions.26 In that study, the authors evaluated mutations at
exons 19 and 21 but did not examine exons 18 and 20. In our
study, we do note a trend of a higher percentage of EGFR
mutants among the ERß and PR positive samples. For all the
samples and those with negative HR stainings, about 40% are
EGFR mutants. However, among those ERß positive and PR
positive samples, there are 60 and 50% EGFR mutants,
respectively, see Table 1. There is a trend that EGFR muta-
tions is associated with ERß-positive tumors, similar to that
seen in the Japanese study. However, significant associations
cannot be demonstrated given the small numbers of positive
staining for the receptors. We did not see a higher proportion
of EGFR mutants among the tumors with ER-positive
expression, This is likely due to the fact that we used
antibodies against the N-terminus of ER. In the Japanese
study, the authors used an antibody against the C-terminus of
ER and a different clone of anti-ERß antibody. The fact that
the Japanese study included more recent patient samples
could also contribute to the different results seen in ER
expression.
In the Japanese study, the authors found a better dis-
ease-free survival for patients with strong expression of ER.
We had used overall survival instead of disease-free survival
to assess for prognostic factors as not all our patients were
early-stage resected NSCLC. On univariate analysis, ad-
vanced stage and significant weight loss were the only factors
that were statistically significantly associated with poorer
outcome. See Table 3. The presence of ERß and Her-2
expression was associated with a statistically nonsignificant
poorer outcome. The negative impact on survival of Her-2
expression has been shown in several other studies.28,29 How-
ever, our finding of a poorer outcome with ERß positivity is
in contrast with other studies13,26 that found a better prognosis
with ERß positivity. The inclusion of patients with all stages
in our study and the small numbers of patients could have
resulted in the differences seen in prognostic significance of
ERß. We also found that the presence of EGFR mutations is
associated with a better prognosis, although it was not statis-
tically significant. This is consistent with other studies that
found that EGFR mutation is an independent prognostic
factor in NSCLC.30
In our study, there is limited expression of HRs in our
patients with NSCLC. There may be a higher proportion of
EGFR mutations among those tumors with positive ERß
receptors, but it is not statistically significant. These suggest
that hormonal factors may not play an important role in the
pathogenesis of lung cancer, even in a patient population with
a high percentage of women. Other factors, genetic or envi-
ronment, may be more important in contributing to the higher
prevalence of lung cancer among East-Asian populations,
women and never smokers. Supporting this is a recent study
that found that selected polymorphic variants in the estrogen
biosynthesis and metabolism pathways are unlikely to be
important genetic modifiers of EGFR mutant NSCLC.31 The
presence of ER/PR/Her-2 staining in NSCLC also means that
a proportion of NSCLC can be ER/PR positive and HR
staining does not exclude the diagnosis of lung cancer.
Correlation with clinical history, examination, imaging, and
IHC with cytokeratin-7, cytokeratin-20, and thyroid tran-
scription factor-1 are also important to determine the origin of
the primary tumor.
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